Exosome-Based Drug Delivery: Prospects in Regenerative Medicine and Cancer

Le résumé fourni par la source

Various cell types produce small extracellular vesicles called exosomes, which are becoming more and more popular as natural delivery systems for medicinal compounds in cancer treatment and regenerative medicine. They are ideal drug delivery vehicles because they are stable, have minimal immunogenicity, and can transport a variety of molecules, including proteins, nucleic acids, and small drugs, across biological barriers. Recent developments in bioengineering have produced "designer exosomes" with enhanced cargo-loading efficiency, superior targeting, and surface features that can be altered. To overcome these issues like poor biodistribution and low drug capacity, exosomes can also be mixed with other nanocarriers, such as liposomes and polymeric nanoparticles. Clinical trials investigating applications in cardiovascular repair, neurological disorders, and targeted oncology are now underway. Exosome-based therapeutics exhibit promise in tissue regeneration and cancer therapy. Large-scale manufacturing, standardization of isolation techniques, regulatory approval, and long-term safety are still obstacles, nevertheless. Future studies will concentrate on creating customized treatments that meet precision medicine objectives, as well as building multifunctional and hybrid exosomes. Exosomes have the potential to become next-generation delivery systems that revolutionize cancer therapy and regenerative medicine treatment approaches with further development.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.